Poland: pharmaceutical sales drop due to COVID-19 2019-2020

The sales value inn the pharmaceutical market over the first 15 days of April 2020 decreased by nearly 14 percent compared to the previous year and by more than 38 percent compared to the same period in March 2020. The most significant drops during the coronavirus epidemic in Poland, i.e., since March 2020, were recorded for OTC drugs, special medical dietary products, and supplements.
For further information about the coronavirus (COVID-19) pandemic, please visit our dedicated Facts and Figures page.

Sales value change in the pharmaceutical market due to the coronavirus (COVID-19) outbreak in Poland from April 2019 to April 2020*, by product category

Characteristic	In comparison to April 15, 2019	In comparison to March 15, 2020
Total market	-13.8%	-38.1%
RX	-14.3%	-29%
Non-RX	-13.3%	-46.5%
OTC	-10.3%	-53%
Supplements	-6.8%	-43.6%
Medical goods	-20.5%	-36.9%
Cosmetics	-18.7%	-25.4%
Special medical dietary products**	-31.9%	-44%
Other	12.8%	-33.2%

Loading statistic...

Download

Source

Show detailed source information?

Already a member?

Source

Use Ask Statista Research Service

Release date

April 2020

More information

Region

Poland

Survey time period

April 1-15 2019, March 1-15 2020, April 1-15 2020***

Supplementary notes

* Sales value in retail prices (excl. VAT). Presented data relate to sale of products used in treatment, prophylaxis and maintenance categorized and included in the pharmacy data database operated by PEX PharmaSequence (Omnibus). Products are classified according to the registration status.
** Special medical dietary products = dietary products for special medical and nutritional uses.
*** Number of days off in researched periods: April 2019 (4), March 2020 (5), April 2020 (5).

Citation formats